1. Home
  2. SRI vs SGMT Comparison

SRI vs SGMT Comparison

Compare SRI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stoneridge Inc.

SRI

Stoneridge Inc.

HOLD

Current Price

$5.57

Market Cap

161.7M

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$5.17

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRI
SGMT
Founded
1965
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
161.7M
169.4M
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
SRI
SGMT
Price
$5.57
$5.17
Analyst Decision
Buy
Strong Buy
Analyst Count
1
8
Target Price
$16.00
$26.38
AVG Volume (30 Days)
191.7K
310.8K
Earning Date
06-12-2026
06-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$824,444,000.00
$2,000,000.00
Revenue This Year
$7.42
N/A
Revenue Next Year
N/A
$4,523.58
P/E Ratio
N/A
N/A
Revenue Growth
18.46
N/A
52 Week Low
$3.54
$1.73
52 Week High
$9.71
$11.41

Technical Indicators

Market Signals
Indicator
SRI
SGMT
Relative Strength Index (RSI) 26.58 41.28
Support Level $5.58 $4.97
Resistance Level $6.35 $6.62
Average True Range (ATR) 0.42 0.28
MACD -0.31 -0.04
Stochastic Oscillator 4.76 8.39

Price Performance

Historical Comparison
SRI
SGMT

About SRI Stoneridge Inc.

Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Its geographic segments include America, South America, Europe and Other.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: